| [1] |
The Food and Drug Administration. Guidance for industry: Diabetes Mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes[EB/OL].(2008-12-19)[2022-09-09].
URL
|
| [2] |
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet, 2017, 390(10100): 1211-1259.
|
| [3] |
Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association[J]. Eur J Heart Fail, 2021, 23(3): 352-380.
|
| [4] |
中华医学会心血管病学分会代谢性心血管疾病学组, 中华心血管病杂志编辑委员会. 心血管病合并糖代谢异常患者心血管风险综合管理中国专家共识[J]. 中华心血管病杂志, 2021, 49(7): 656-672.
|
| [5] |
Häring H-U, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial [J]. Diabetes Care, 2014, 37(6): 1650-1659.
|
| [6] |
Kohler S, Zeller C, Iliev H, et al. Safety and tolerability of Empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials[J]. Adv Ther, 2017, 34(7): 1707-1726.
|
| [7] |
Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017[J]. Cardiovasc Diabetol, 2018, 17(1):83.
|
| [8] |
Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial[J]. Circulation, 2019, 139(11): 1384-1395.
|
| [9] |
Mordi NA, Mordi IR, Singh JS, et al. Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF trial[J]. Circulation, 2020, 142(18):1713-1724.
|
| [10] |
Packer M, Butler J, Filippatos GS, et al. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial[J]. Eur J Heart Fail, 2019, 21(10): 1270-1278.
|
| [11] |
Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure[J]. N Engl J Med, 2020, 383(15): 1413-1424.
|
| [12] |
Zannad F, Ferreira JP, Pocock SJ, et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced[J]. Circulation, 2021, 143(4): 310-321.
|
| [13] |
Butler J, Anker SD, Filippatos G, et al. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial[J]. Eur Heart J, 2021, 42(13): 1203-1212.
|
| [14] |
Packer M, Anker SD, Butler J, et al. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial[J]. Eur Heart J, 2021, 42(6): 671-680.
|
| [15] |
Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction[J]. J Am Coll Cardiol, 2021, 77(3): 243-255.
|
| [16] |
Lee M, Brooksbank K, Wetherall K, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)[J]. Circulation, 2021, 143(6):516-525.
|
| [17] |
Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction[J]. N Engl J Med, 2021, 385(16):1451-1461.
|
| [18] |
Butler J, Filippatos G, Jamal Siddiqi T, et al. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial[J]. Circulation, 2022, 145(3): 184-193.
|
| [19] |
Ferreira JP, Butler J, Zannad F, et al. Mineralocorticoid receptor antagonists and empagliflozin in patients with heart failure and preserved ejection fraction[J]. J Am Coll Cardiol, 2022, 79(12): 1129-1137.
|
| [20] |
Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial[J]. Nat Med, 2022, 28(3): 568-574.
|
| [21] |
Kosiborod MN, Angermann CE, Collins SP, et al. Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure: results from the EMPULSE trial[J]. Circulation, 2022, 146(4):279-288.
|
| [22] |
Patorno E, Pawar A, Wexler DJ, et al. Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study[J]. Diabetes Obes Metab, 2022, 24(3):442-454.
|
| [23] |
Sheu WH, Seino Y, Tan EC, et al. Healthcare resource utilization in patients treated with empagliflozin in East Asia[J]. J Diabetes Investig, 2022, 13(5):810-821.
|
| [24] |
Filion KB, Lix LM, Yu OH, et al. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study[J]. BMJ, 2020, 370:m3342.
|
| [25] |
Sha S, Polidori D, Heise T, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus[J]. Diabetes Obes Metab, 2014, 16(11):1087-1095.
|
| [26] |
Pfeifer M, Townsend RR, Davies MJ, et al. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis[J]. Cardiovasc Diabetol, 2017, 16(1):29.
|
| [27] |
Nakayama H, Ohtsuka Y, Kawahara M, et al. Changes in body composition during SGLT2 inhibitor treatment and their relevance to the improvement of insulin sensitivity[J]. Diabetes Res Clin Pract, 2016, 120: s50-s51.
|
| [28] |
Ridderstråle M, Rosenstock J, Andersen KR, et al. Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial[J]. Diabetes Obes Metab, 2018, 20(12):2768-2777.
|
| [29] |
Iemitsu K, Iizuka T, Takihata M, et al. Factors influencing changes in hemoglobin A1c and body weight during treatment of type 2 diabetes with ipragliflozin: interim analysis of the ASSIGN-K study[J]. J Clin Med Res, 2016, 8(5): 373-378.
|
| [30] |
Verma S, Rawat S, Ho KL, et al. Empagliflozin increases cardiac energy production in diabetes: novel translational Insights into the heart failure benefits of SGLT2 inhibitors[J]. JACC Basic Transl Sci, 2018, 3(5): 575-587.
|
| [31] |
Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics[J]. J Am Coll Cardiol, 2019, 73(15):1931-1944.
|
| [32] |
Lee TI, Chen YC, Lin YK, et al. Empagliflozin Attenuates myocardial sodium and calcium dysregulation and reverses cardiac remodeling in streptozotocin-Induced diabetic Rats[J]. Int J Mol Sci, 2019, 20(7): 1680-1698.
|
| [33] |
Zhou H, Wang S, Zhu P, et al. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission[J]. Redox Biol, 2018, 15: 335-346.
|
| [34] |
Wu P, Wen W, Li J, et al. Systematic review and meta-Analysis of randomized controlled trials on the effect of SGLT2 inhibitor on blood leptin and adiponectin level in patients with type 2 diabetes[J]. Horm Metab Res, 2019, 51(8): 487-494.
|
| [35] |
Mcdonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [J]. Eur Heart J, 2021, 42(36): 3599-3726.
|